| abstract |
The present invention provides methods and compositions for screening, diagnosis and prognosis of a neuropsychiatric or neurological condition including BAD, schizophrenia and vascular dementia for monitoring the effectiveness of treatment of all of the noted conditions, and for drug development. BAD-Associated Features (DFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides BAD-Associated Protein Isoforms (DPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated DPIs, antibodies immunospecific for DPIs, and kits comprising the aforesaid. |